Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Conflict Of Interest Reform Fight Reignites Following Panel Revelations

This article was originally published in The Tan Sheet

Executive Summary

Advisory committee conflict of interest reform draws increased attention in the wake of concerns raised about a recent Reproductive Health panel meeting.

You may also be interested in...



FDA Advisory Committees Would Get Patient Influence Under Hagan Bill

Adjusting advisory committee conflict of interest rules becomes a high-priority issue in reauthorizing FDA’s drug user fee program. With several bills proposing to loosen the rules, Sen. Hagan’s draft FDA reform legislation could bring the most changes.

US FDA's FY 2023 User Fees Finally Revealed

Several fees for prescription drug, generic drug, and biosimilar applications are set to increase, although some also will drop.

New Name, Old Problems: US FDA’s Cell And Gene Therapy Office Still Facing Growth Challenges

The group will be called the Office of Therapeutic Products, but needs more people to handle its increasing workload.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS105520

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel